In this Review, Simpson et al. summarize the emergent understanding of molecular subtypes of small cell lung cancer (SCLC). They discuss how intratumour heterogeneity and dynamic tumour plasticity may challenge the success of immune and molecular subtype-targeted therapies and argue that combination therapies, monitored by serial liquid biopsy-based biomarkers, will be needed to improve the outcomes of patients with SCLC.